ライフサイエンスコーパス: evaluation study

1 rial and the Careful Urinary Tract Infection Evaluation Study).

2 a Study and the African Descent and Glaucoma Evaluation Study.

3 Cross-discipline evaluation study.

4 a Study and the African Descent and Glaucoma Evaluation Study.

5 a Study and the African Descent and Glaucoma Evaluation Study.

6 cipating in the Pravastatin Inflammation/CRP Evaluation Study.

7 system, MedLEE, and performed a preliminary evaluation study.

8 from the DARE (Drug-Induced Arrhythmia Risk Evaluation) study.

9 w Reserve versus Angiography for Multivessel Evaluation) study.

10 Sonographic Coronary Obstruction Prospective Evaluation) study.

11 ors in Non-Ischemic cardiomyopathy Treatment Evaluation) study.

12 Rs and the radioligand was suitable for drug evaluation studies.

13 eed to be better documented through rigorous evaluation studies.

14 t is, aetiological, longitudinal and service evaluation studies.

15 date reference tests for the conduct of test evaluation studies.

16 le of 107 lens images from the Salisbury Eye Evaluation Study, a digital cortical cataract grading al

17 Data from the Salisbury Eye Evaluation Study, a population-based sample of 2,520 adu

18 (DIGS) and the African Descent and Glaucoma Evaluation Study (ADAGES) were classified with optic dis

19 90 eyes) enrolled in the African Descent and Evaluation Study (ADAGES) with a diagnosis of glaucomato

20 tudy (DIGS) and African Descent and Glaucoma Evaluation Study (ADAGES) with at least 2 years of follo

21 Glaucoma Study-DIGS and African Descent and Evaluation Study-ADAGES) were observed with standard ach

22 e, randomised, open-label, blinded end-point evaluation study, adults with supratentorial ischaemic s

23 to participants in the Aichi Gerontological Evaluation Study (AGES) Project in 2003.

24 the multicenter African Descent and Glaucoma Evaluation Study and Diagnostic Innovations in Glaucoma

25 sed the control groups of the Asthma Control Evaluation study and the Inner City Anti-IgE Therapy for

26 We did a field evaluation study between Oct 1, 2014, and April 30, 2016

27 onal Study was a prospective diagnostic test evaluation study conducted in 7 centers.

28 ons for a standardized approach for economic evaluation study designs (e.g., common asthma outcomes,

29 implemented to reduce As exposure, although evaluation studies for these efforts are rare in the lit

30 benzodiazepines as second line, but very few evaluation studies have been reported.

31 for the 1945-1965 birth cohort, research and evaluation studies in settings where persons who inject

32 Further efficacy evaluation studies in the P. knowlesi-rhesus monkey spor

33 ed data from the RALES (Randomized Aldactone Evaluation Study) in 1,658 patients with New York Heart

34 ATERIAL/METHODS: This observational clinical evaluation study included 224 patients who were referred

35 In this multi-laboratory evaluation study including 11 sites worldwide, we demons

36 The Japan Gerontological Evaluation Study is a nationwide cohort study of individ

37 study was based on the Japan Gerontological Evaluation Study (JAGES) Cohort Study data.

38 In our clinical evaluation study, MCM2-positive cells were retrieved fro

39 Data from major program evaluation studies of existing substance abuse treatment

40 ons are intended for tuberculosis diagnostic evaluation studies of symptomatic children with clinical

41 models (Seattle Heart Failure Score, ESCAPE [Evaluation Study of Congestive Heart Failure and Pulmona

42 ndomized or registry portions of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmona

43 eart failure (n=657) and (2) patients in the Evaluation Study of Congestive Heart Failure and Pulmona

44 We analyzed the Evaluation Study of Congestive Heart Failure and Pulmona

45 Subjects in the Evaluation Study of Congestive Heart Failure and Pulmona

46 (Evaluation Study of Congestive Heart Failure and Pulmona

47 ion were created using data from the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmona

48 were measured in 287 patients in the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmona

49 We examined the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmona

50 Based on the results of the Evaluation Study of Congestive Heart Failure and Pulmona

51 In the Evaluation Study of Congestive Heart Failure and Pulmona

52 heart failure (HF) patients enrolled in the Evaluation Study of Congestive Heart Failure and Pulmona

53 CORE (Heart Strategies Concentrating on Risk Evaluation) study participants.

54 eral design and interpretation of diagnostic evaluation studies, particularly in the field of respira

55 After the Randomized Aldactone Evaluation Study (RALES) demonstrated a 30% mortality be

56 fter publication of the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older pa

57 25 mg or placebo in the Randomized Aldactone Evaluation Study (RALES) trial.

58 aily or placebo, in the Randomized Aldactone Evaluation Study (RALES).

59 With this report (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked incre

60 a With Extremely Serious Operative Mortality Evaluation) study randomized trial and registry of high-

61 The CAFE (Conduit Artery Function Evaluation) study showed less effective central aortic p

62 An unbiased evaluation study shows that for nsSNPs with sufficient e

63 nt is relevant for animal models and vaccine evaluation studies that use nonhuman complement.

64 We performed a preliminary evaluation study that shows encouraging results of our s

65 n the PREPARE (Primary Prevention Parameters Evaluation) study, these prior strategies were combined

66 ue is uniformly accepted and used in vaccine evaluation studies to determine the acceptable level of

67 globally commercialized supports use of meta-evaluation studies to test discrimination power among mo

68 This was a pilot evaluation study to identify factors that facilitated/hi

69 l studies in HOPE (Heart Outcomes Prevention Evaluation) study-type patients, the aims of this study

70 A-TT first-introducer countries, and several evaluation studies were conducted to estimate the vaccin

71 Subsequently, evaluation studies were performed on isolated perfused r

72 ucoma Study and African Descent and Glaucoma Evaluation Study were included, based on the appearance

73 a Study and the African Descent and Glaucoma Evaluation Study were included.

74 ne thousand participants enrolled in a field evaluation study, were linked to population-level health